

KFIN/CERT13(3)/DEC/2022 January 6, 2023

Mr. Ajay Nadkarni M/s. GlaxoSmithKline Pharmaceuticals Limited Dr. Annie Besant Road Worli Mumbai-400025.

Sub: Investor Grievance Certificate for the quarter ended December 31, 2022.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended December 31, 2022.

Description of	Opening	Received during the	Attended/Resolved	Pending as on
Complaint	Balance as on	Period 01.10.2022	during the Period	31.12.2022
	01.10.2022	to 31.12.2022	01.10.2022 to	
			31.12.2022	
Non-receipt of	NIL	13	13	NIL
Dividend				
Non-receipt of	NIL	NIL	NIL	NIL
Annual reports				
Non receipt of	NIL	01	01	NIL
share certificates				
SEBI	NIL	01	01	NIL
Stock Exchange	NIL	03	03	NIL
Total	NIL	18	18	NIL

This is for your information and record.

Thanking you,

Yours faithfully For KFin Technologies Private Limited

Rajitha Cholleti Dy. General Manager

KFin Technologies Private Limited

(Formerly known as "Karvy Fintech Private Limited")

## **Registered & Corporate Office**

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 5000 Ph : +91 40 6716 2222, 7961 1000 | https://www.kfintech.com | CIN : U72400TG2017PTC117649